Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (121-130 of 228) with videos related to

Pageof 23
Sort By:
Annals of Surgery|May 15, 2019
Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE TrialFlorian Fitzal, Vesna Bjelic-Radisic, Michael Knauer, et al.
NPJ Breast Cancer|April 17, 2026
Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trialsSimon Udovica, Rupert Bartsch, Christian F Singer, et al.
ESMO Open|November 16, 2016
Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancersAnna S Berghoff, Sophie Schur, Lisa M Füreder, et al.
BMC Cancer|March 17, 2006
Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational studyRupert Bartsch, Catharina Wenzel, Dagmar Hussian, et al.
ESMO Open|November 16, 2016
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of ViennaBarbara Kiesewetter, Markus Raderer, Günther G Steger, et al.
Journal of Neuro-Oncology|June 9, 2007
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancerRupert Bartsch, Andrea Rottenfusser, Catharina Wenzel, et al.
The Oncologist|June 15, 2022
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert PanelBolivar Arboleda, Rupert Bartsch, Evandro de Azambuja, et al.
Cancer Medicine|July 27, 2016
Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapyRuth Exner, Monika Sachet, Tobias Arnold, et al.
Clinical Breast Cancer|March 8, 2021
Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast CancerChristian Jackisch, Carlos H Barcenas, Rupert Bartsch, et al.
Oncoimmunology|November 29, 2023
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancerMaximilian Marhold, Simon Udovica, Anna Halstead, et al.
Pageof 23

Showing results (121-130 of 228) with videos related to

Sort By:
Pageof 23
Annals of Surgery|May 15, 2019
Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE TrialFlorian Fitzal, Vesna Bjelic-Radisic, Michael Knauer, et al.
NPJ Breast Cancer|April 17, 2026
Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trialsSimon Udovica, Rupert Bartsch, Christian F Singer, et al.
ESMO Open|November 16, 2016
Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancersAnna S Berghoff, Sophie Schur, Lisa M Füreder, et al.
BMC Cancer|March 17, 2006
Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational studyRupert Bartsch, Catharina Wenzel, Dagmar Hussian, et al.
ESMO Open|November 16, 2016
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of ViennaBarbara Kiesewetter, Markus Raderer, Günther G Steger, et al.
Journal of Neuro-Oncology|June 9, 2007
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancerRupert Bartsch, Andrea Rottenfusser, Catharina Wenzel, et al.
The Oncologist|June 15, 2022
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert PanelBolivar Arboleda, Rupert Bartsch, Evandro de Azambuja, et al.
Cancer Medicine|July 27, 2016
Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapyRuth Exner, Monika Sachet, Tobias Arnold, et al.
Clinical Breast Cancer|March 8, 2021
Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast CancerChristian Jackisch, Carlos H Barcenas, Rupert Bartsch, et al.
Oncoimmunology|November 29, 2023
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancerMaximilian Marhold, Simon Udovica, Anna Halstead, et al.
Pageof 23